论文部分内容阅读
Background: Anti-androgen/androgen receptor (AR) agents,as the first-line hormone therapy,have been commonly administrated in prostate cancer (PCa) patients.However,the response of patients to these agents is temporary,the diseases inevitably developed to the androgen-refractory stage,and lost the response to these agents.